DHRDHR
US • —
$190.48
P/E
36.81
PEG
122.69
FCF Yield
—
Rev Growth YoY
+4.0% YoY
Gross Margin
59.0%
Health Score
—
D/E Ratio
0.35
Confidence
MEDIUM
Business Snapshot
Danaher Corporation operates in the life sciences and diagnostics sectors, providing a range of analytical instruments, reagents, and consumables used in research, clinical, and industrial applications. The company holds a strong competitive position as a diversified science and technology leader with a broad portfolio of established brands. The market capitalisation is unavailable for this analysis, but Danaher is typically classified as a large-cap entity given its scale and global footprint. A defining characteristic is its focus on continuous improvement through the Danaher Business System, which drives operational efficiency and acquisition integration.
Financial Health
Score: N/A Gross margin stands at 59.0%, though prior year data is not available for comparison, while net margin is 14.9%. The balance sheet appears healthy with a debt-to-equity ratio of 0.35x, indicating conservative leverage, and a current ratio of 1.87x, suggesting solid short-term liquidity...
Risk Assessment
- VALUATION — P/E of 36.81x is significantly above the sector average of 22x, implying a high premium that may not be justified by current growth.
- REVENUE DECELERATION — Revenue growth of 4.0% YoY is modest, and without quarterly data, there is no evidence of accelerating momentum.
- EARNINGS QUALITY — Earnings growth of just 0.3% YoY is effectively flat, raising questions about the company's ability to generate earnings expansion.
- TECHNICALS — RSI, MACD, and moving average data are unavailable for this period; momentum cannot be independently confirmed....
Score: N/A Gross margin stands at 59.0%, though prior year data is not available for comparison, while net margin is 14.9%. The balance sheet appears healthy with a debt-to-equity ratio of 0.35x, indicating conservative leverage, and a current ratio of 1.87x, suggesting solid short-term liquidity. Free cash flow figures are not available, preventing a full assessment of cash generation capacity. Based on the available data, the company maintains a prudent capital structure, which supports reinvestment and potential for shareholder returns, though the lack of cash flow data limits a complete health evaluation.
- VALUATION — P/E of 36.81x is significantly above the sector average of 22x, implying a high premium that may not be justified by current growth. - REVENUE DECELERATION — Revenue growth of 4.0% YoY is modest, and without quarterly data, there is no evidence of accelerating momentum. - EARNINGS QUALITY — Earnings growth of just 0.3% YoY is effectively flat, raising questions about the company's ability to generate earnings expansion. - TECHNICALS — RSI, MACD, and moving average data are unavailable for this period; momentum cannot be independently confirmed.
Unlock the full AI report
Full 8-section analysis includes:
Metric deep-dives